Source link : https://www.newshealth.biz/health-news/second-drug-for-benign-synovial-tumor-condition-wins-fda-approval/
(MedPage Today) — The FDA approved the small-molecule inhibitor vimseltinib (Romvimza) for adults with symptomatic tenosynovial giant cell tumor (TGCT), a rare, non-malignant, but debilitating, condition arising in the synovium, the agency announced… Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/114242 Author : Publish date : 2025-02-14 22:06:43 Copyright for syndicated content belongs to the linked Source.
Author : News Health
Publish date : 2025-02-14 22:06:43
Copyright for syndicated content belongs to the linked Source.